Noticeably, as a pro-inflammatory and neuroprotective signaling molecule, leptin reduction should be weighed against the pathological hyperleptinemia in neuroinflammatory conditions such as MS, as opposed to its protective effects in chronic neurodegenerative diseases such as AD. This evidence concerns the gene LEP and myeloid sarcoma.